权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Diagnosing and Targeting Mechanisms of Diuretic Resistance in Heart Failure

心力衰竭利尿抵抗的诊断和靶向机制

基本信息

批准号：
8947108
负责人：
JEFFREY M TESTANI
金额：
$ 80.16万
依托单位：
YALE UNIVERSITY
依托单位国家：
美国
项目类别：
财政年份：
2015
资助国家：
美国
起止时间：
2015-08-01 至 2020-04-30
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/8947108
关键词：
Accounting Acute Algorithms Body Weight decreased Chemistry Data Diagnosis Distal Diuresis Diuretics Dose Early treatment Enrollment Epidemic Expenditure Failure Fluid overload Freedom Funding Goals Gold Heart failure Henle&apos s loop Hospitalization Hospitals Hour Inpatients Investigation Kidney Laboratories Left Length of Stay Liquid substance Lithium Low Cardiac Output Measures Medicare Methodology Methods Natriuresis Nephrons Oral Outcome Outpatients Patients Pharmaceutical Preparations Phenotype Prevalence Randomized Research Research Personnel Resistance Resistance development Sampling Serum Site Sodium Speed Spottings Symptoms Techniques Testing Thiazide Diuretics Toxic effect Tubular formation United States National Institutes of Health Urine Weight Gain accurate diagnosis beneficiary improved in vivo individualized medicine personalized medicine prevent public health relevance rapid diagnosis resistance mechanism response saluretic tool treatment strategy wasting

项目摘要

DESCRIPTION (provided by applicant): The overarching goal of this proposal is to create and validate pragmatic tools to rapidly detect and define the mechanism of diuretic resistance (DR), allowing individualized therapy in patients with acute decompensated heart failure (ADHF). ADHF is the most common hospital discharge diagnosis among Medicare beneficiaries and accounts for more than half of all heart failure (HF) related expenditures. This epidemic of ADHF is primarily driven by fluid and sodium overload, leaving the loop diuretics as the most commonly used medications to treat and prevent ADHF. Unfortunately, a loss of response to loop diuretics, termed diuretic resistance (DR), is common and contributes to a vicious cycle of out of hospital fluid/sodium retention, incomplete in-hospital decongestion, followed by post-discharge re-accumulation of fluid/sodium and worsened outcomes. Despite its importance, the speed and fidelity with which we can diagnose DR is extremely limited. This results in potentially avoidable hospitalization of outpatients and "wasted" hospital days where effective diuresis does not occur in inpatients. Once recognized, tools to determine the mechanism for DR and thus individualize treatment are nonexistent. Although multiple mechanisms contribute to loop DR, two therapeutically distinct groups exist: (1) inadequate effect at the tubular site of action, whih requires treatment with increased dose or delivery of loop diuretic and (2) compensatory distal tubular sodium reabsorption, which requires treatment with sequential nephron blockade (i.e., thiazide diuretics). Our inability to differentiate these mechanisms leaves trial and error as the only method to treat DR, further delaying effective diuresis and exposing patients to medications with known toxicities when the empiric choice is incorrect. In the present study, we will enroll 200 ADHF patients and evaluate them longitudinally through key transitions in loop diuretic therapy (early into IV therapy, late IV therapy, after conversion to oral diuretics, and 5-7 days post discharge). Patients with significant DR during early IV therapy will be randomized to increased loop diuretic dose or add on thiazide diuretic stratified by the DR mechanism. The data generated through the above investigation will allow us to: (1) develop inexpensive and efficient tools to predict diuretic response in a reliable and timely manner; (2) understand the prevalence of therapeutically targetable mechanisms of DR using endogenous lithium clearance, a "gold standard" technique to query in vivo proximal tubular/loop of Henle sodium handling; (3) develop methodology to differentiate DR mechanisms using common/inexpensive laboratory tests; and (4) provide proof of concept that mechanistically tailored diuretic therapy can improve natriuresis. Our preliminary data suggests that diagnosis and phenotyping of DR can in fact be done with excellent accuracy (AUC =~0.9) using universally available urine/serum chemistries. At the conclusion of this research, our goal is to provide clinicians and researchers with a workable tool to accurately/rapidly diagnose and phenotype DR allowing individualized diuretic therapy for both inpatients and outpatients with heart failure.